FDA approves Eli Lilly's Inluriyo with Verzenio for advanced breast cancer

The FDA approved Eli Lilly's Inluriyo in combination with its cancer drug Verzenio for patients with an advanced form of breast cancer, STAT News reported. A Phase 3 study showed the combination cut the risk of progression or death by 47% versus imlunestrant alone.

Detected & updated continuously · Source: Nebula